These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9401905)

  • 1. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E; Bellone J; Aimaretti G; Arvat E; Benso L; Deghenghi R; Camanni F; Ghigo E
    J Pediatr Endocrinol Metab; 1997; 10(5):491-7. PubMed ID: 9401905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E; Ceda GP; Di Vito L; Ramunni J; Gianotti L; Broglio F; Deghenghi R; Ghigo E
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E; Gianotti L; Broglio F; Maccagno B; Bertagna A; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.
    Bellone J; Bellone S; Aimaretti G; Valetto MR; Baffoni C; Corneli G; Origlia C; Arvat E; Ghigo E
    J Endocrinol Invest; 2000 Mar; 23(3):158-62. PubMed ID: 10803472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.
    Bellone J; Aimaretti G; Bartolotta E; Benso L; Imbimbo BP; Lenhaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1090-4. PubMed ID: 7714074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.